CD20 Protein, Human, Recombinant (His & Avi)

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.

规格	价格/CNY		数量
100 μg	￥ 2,960	5日内发货
500 μg	￥ 11,800	5日内发货
1 mg	￥ 19,700	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 2,960

5日内发货

500 μg

￥ 11,800

5日内发货

1 mg

￥ 19,700

5日内发货

生物活性

Immobilized Human CD20, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.33μg/ml determined by ELISA.

产品描述

种属	Human
表达系统	E. coli
标签	C-His-Avi
蛋白编号	P11836-1
别名	MS4A2, Ly-44, LEU-16, MS4A1, Bp35, CD20 receptor, CVID5, MS4A-1, B1, S7, CD20S7, CD20
蛋白构建	Recombinant Human CD20/MS4A1 Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus. It contains Ile141-Ser188.[Accession \|P11836-1]
蛋白纯度	> 95% as determined by Tris-Bis PAGE
分子量	The protein has a predicted MW of 16.8 kDa same as Tris-Bis PAGE result.

内毒素	Less than 1EU per μg by the LAL method.
缓冲液	Supplied as 0.22μm filtered solution in 20mM PB, 10% Glycerol, 0.4M Urea, 1mM GSH, 0.1mM GSSG (pH 7.0).
存储	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.